LifeTrac SugarTrac bloodless Glucose Meter - Real or Hoax?
I saw where LifeTrac finished beta Testing a glucose meter that doesn't use blood or isn't a continous meter like the GlucoWatch. Is this real or just some Internet Hoax? Life without pricking would be nice ....
I asked a couple of other volunteers about LifeTrac and none had heard of a beta test for a non envasive glucose meter. I also checked the web and other sites and could find nothing. It's possible I have missed something, but as we all know and as you said, we have to be a little cautious when it comes to somethings on the internet. You did'nt say where you saw this, but personally, unless I know it is a reliable source, I try to verify like you did. My son has had type 1 for 18 years and would also love a meter like this. If anyone else has indeed heard of it, we may see a comment. Best of luck.
After further research, I have found and contacted LifeTrac and hope for a response soon. I'm still being careful to fully examine this technology. I have heard of infra light tech many years ago, but have not seen anything coming out for public use. I will post again when I get something that I feel is a reliable response.
I actually gave them a call. They're located in Maine. And tehy're not the only company doing this - seems since the late 60s some 30 companies have researched and actually developed the technology into a viable product .... they just never brought it to market. Most of the calls for information to them have been in reference to it's use with children.
This month they start Phase II of their trials with production grade model; it *does* work (with somewhat better accuracy than LifeScan's OneTouch Ultras); and sometime in 2004 we should start seeing the device in use. They don't seem to have a problem with Glucose monitor manufacturers lining up to market/produce the technology either.
The device has to be written up the medical journals and get FDA approval. But the technology is here. Their website's out of date at the moment, but it's at:
A new noninvasive tool uses electromagnetic waves to measure glucose levels.
By Jennifer Chu
This won’t hurt a bit: A thumb-pad sensor designed by researchers at Baylor University monitors glucose levels noninvasively. The spiral-shaped circuit at the center of the device (pink) emits electromagnetic waves; the electrical properties of a thumb placed on the spiral change how energy passes through the circuit. The Baylor researchers are analyzing the changes in energy to gauge glucose levels. Credit: Randall Jean/Baylor University
THE BOSTON GLOBE
March 14, 2008
A small Franklin company says it is developing a novel device that could potentially let diabetics continuously monitor their blood-sugar levels — without having to draw blood.
Echo Therapeutics Inc. is expected to say today the device passed one of its first key tests, a pilot study with two dozen patients in the intensive-care unit at Tufts Medical Center in Boston. The Symphony system, a disc about the size of a half dollar, is designed to read glucose levels through the skin and transmit the information wirelessly to a nearby computer or hand-held meter. Currently, diabetes patients must normally ***** their skin to draw a few drops of blood and place them on a measuring strip.
“I think it’s extremely promising,” said Dr. Stanley Nasraway, a Tufts University School of Medicine professor and director of surgical intensive-care units at the medical center. Nasraway said Echo’s experimental device appeared to be reliable, relatively accurate, and easy to use, though he cautioned that it must first be tested in much larger clinical trials with a wider group of patients.
If successful in broader trials, Echo hopes to win approval from the US Food and Drug Administration to market the device as soon as late next year to both hospitals and diabetics for home use. Company executives estimate at least 1.5 million diabetics in the United States currently test their blood-sugar levels twice a day or more, and could potentially benefit from the device, making it a multibillion-dollar market.
“It’s an enormous market opportunity,” said Harry Mitchell, chief financial officer.
To be sure, Echo is still tweaking the device. It now uses ultrasound technology to expose capillary blood vessels to measure blood-sugar levels. But in future versions, the device will scrape off the outermost layer of skin.
Other companies have failed in efforts to market alternatives to needles for diabetics. In 2001, Cygnus Inc. won FDA approval for its GlucoWatch, a blood-sugar meter that could be worn like a wristwatch.
But the device was eventually discontinued amid complaints it was not accurate and caused skin irritation in some users. Johnson & Johnson, which now reportedly owns the technology, did not return calls seeking comment.
In addition, several companies, including Pfizer Inc. and Eli Lilly & Co., recently scrapped projects to develop an inhalable form of insulin, used to regulate blood-sugar levels. Eli Lilly was working with Cambridge-based Alkermes Inc. on the technology.
Echo also would face competition from other companies, such as DexCom Inc. of San Diego and Medtronic Inc. of Minneapolis, which have developed systems to let patients insert a glucose sensor just under the skin. The sensors constantly monitor glucose levels for up to a week before they need to be replaced. Echo says its system is superior because patients wouldn’t have to use a needle to insert the sensor, which could be placed on the body like a bandage.
But Echo would likely need to raise tens of millions of dollars for clinical trials and other work to bring the product to market. The company had $2.3 million in cash as of September.
“We see lots of interesting ideas,” said Medtronic spokesman Steven Cragle, “but actually getting them approved is a much different story.”
And so far, investors do not seem impressed by Echo’s potential. Its stock closed at $1.35 Wednesday, down from a high of $31.70 in 2004. Echo’s market value is just $25 million.
“We have really just started telling our story,” said Echo chief executive Patrick Mooney. “It’s not a negative. I think Wall Street just doesn’t know who we are.”
Mooney said the Echo technology was originally pioneered in 1996 at Robert S. Langer ScD ’74’s lab at the Massachusetts Institute of Technology, and then further developed by Sontra Medical Corp., which merged with Echo last year.
The American Diabetes Association, which promotes diabetes research, declined to comment.
Copyright 1994-2016 MedHelp International. All rights reserved.
MedHelp is a division of Aptus Health.
This site complies with the HONcode standard for trustworthy health information.
The Content on this Site is presented in a summary fashion, and is intended to be used for educational and entertainment purposes only. It is not intended to be and should not be interpreted as medical advice or a diagnosis of any health or fitness problem, condition or disease; or a recommendation for a specific test, doctor, care provider, procedure, treatment plan, product, or course of action. Med Help International, Inc. is not a medical or healthcare provider and your use of this Site does not create a doctor / patient relationship. We disclaim all responsibility for the professional qualifications and licensing of, and services provided by, any physician or other health providers posting on or otherwise referred to on this Site and/or any Third Party Site. Never disregard the medical advice of your physician or health professional, or delay in seeking such advice, because of something you read on this Site. We offer this Site AS IS and without any warranties. By using this Site you agree to the following Terms and Conditions. If you think you may have a medical emergency, call your physician or 911 immediately.